Alzheimer’s Drug Discovery Foundation (ADDF): Accelerating DRUG DISCOVERY for Frontotemporal Dementias (2012 ADDF-AFTD RFP) - LOI

The ADDF and AFTD seek to accelerate and support drug discovery for FTD and related dementias. Priority areas for this program include:
• Target validation studies
• Development and testing of novel high throughput screening assays
• Medicinal chemistry on lead compounds
• Identification and in vitro testing of potentially disease modifying lead compounds
• ADME, toxicology, pharmacokinetics, pharmacodynamics on lead compounds
• Testing of lead compounds in a relevant animal model for preclinical proof of concept
• Development of biomarkers to accelerate drug development and early diagnosis
• Innovative pilot clinical trials
PLEASE NOTE: THIS FUNDING WILL NOT SUPPORT APPLICATIONS FOR BASIC RESEARCH.
The deadline date for applications is September 20, 2012. Submission of a Letter of Intent (LOI) is required prior to September 6th, 2012.
Funding: $150K for 1 year. http://www.alzdiscovery.org/